These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 9480509)

  • 21. Failure to achieve a PSA level Mitchell DM; McAleese J; Park RM; Stewart DP; Stranex S; Eakin RL; Houston RF; O'Sullivan JM
    Int J Radiat Oncol Biol Phys; 2007 Dec; 69(5):1467-71. PubMed ID: 17689886
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effectiveness of adjuvant intermittent endocrine therapy following neoadjuvant endocrine therapy and external beam radiation therapy in men with locally advanced prostate cancer.
    Yamanaka H; Ito K; Naito S; Tsukamoto T; Usami M; Fujimoto H; Matsuoka N; Fukui I; Harada M; Ohashi Y; Kotake T; Kakizoe T
    Prostate; 2005 Apr; 63(1):56-64. PubMed ID: 15468166
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Risk-adapted androgen deprivation and escalated three-dimensional conformal radiotherapy for prostate cancer: Does radiation dose influence outcome of patients treated with adjuvant androgen deprivation? A GICOR study.
    Zapatero A; Valcárcel F; Calvo FA; Algás R; Béjar A; Maldonado J; Villá S
    J Clin Oncol; 2005 Sep; 23(27):6561-8. PubMed ID: 16170164
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical results of combined treatment conformal high-dose-rate iridium-192 brachytherapy and external beam radiotherapy using staging lymphadenectomy for localized prostate cancer.
    Hiratsuka J; Jo Y; Yoshida K; Nagase N; Fujisawa M; Imajo Y
    Int J Radiat Oncol Biol Phys; 2004 Jul; 59(3):684-90. PubMed ID: 15183471
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Improved biochemical outcome with adjuvant radiotherapy after radical prostatectomy for prostate cancer with poor pathologic features.
    Vargas C; Kestin LL; Weed DW; Krauss D; Vicini FA; Martinez AA
    Int J Radiat Oncol Biol Phys; 2005 Mar; 61(3):714-24. PubMed ID: 15708249
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Radiotherapy combined with hormonal therapy (RT-HT) in prostate cancer patients with low, intermediate, and high risk of biochemical recurrence: perspective and therapeutic gain analysis.
    Milecki P; Kwias Z; Martenka DJ
    Neoplasma; 2007; 54(1):7-15. PubMed ID: 17203887
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Endocrine treatment of prostate cancer.
    Tammela T
    J Steroid Biochem Mol Biol; 2004 Nov; 92(4):287-95. PubMed ID: 15663992
    [TBL] [Abstract][Full Text] [Related]  

  • 28. High-dose radiation employing external beam radiotherapy and high-dose rate brachytherapy with and without neoadjuvant androgen deprivation for prostate cancer patients with intermediate- and high-risk features.
    Vargas C; Martínez A; Galalae R; Demanes J; Harsolia A; Schour L; Nuernberg N; Gonzalez J
    Prostate Cancer Prostatic Dis; 2006; 9(3):245-53. PubMed ID: 16786040
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413.
    Roach M; DeSilvio M; Lawton C; Uhl V; Machtay M; Seider MJ; Rotman M; Jones C; Asbell SO; Valicenti RK; Han S; Thomas CR; Shipley WS;
    J Clin Oncol; 2003 May; 21(10):1904-11. PubMed ID: 12743142
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High-dose-rate iridium-192 afterloading therapy combined with external beam radiotherapy for T1c-T3bN0M0 prostate cancer.
    Jo Y; Hiratsuka J; Fujii T; Takenaka A; Fujisawa M
    Urology; 2004 Sep; 64(3):556-60. PubMed ID: 15351592
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nadir prostate-specific antigen within 12 months after radiotherapy predicts biochemical and distant failure.
    Ray ME; Levy LB; Horwitz EM; Kupelian PA; Martinez AA; Michalski JM; Pisansky TM; Zelefsky MJ; Zietman AL; Kuban DA
    Urology; 2006 Dec; 68(6):1257-62. PubMed ID: 17141830
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Hormone therapy of locally advanced and metastatic prostate carcinoma].
    Rübben H
    Praxis (Bern 1994); 2001 Sep; 90(38):1641-4. PubMed ID: 11675917
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Factors affecting recurrence rates after prostatectomy or radiotherapy in localized prostate carcinoma patients with biopsy Gleason score 8 or above.
    Kupelian PA; Buchsbaum JC; Elshaikh M; Reddy CA; Zippe C; Klein EA
    Cancer; 2002 Dec; 95(11):2302-7. PubMed ID: 12436435
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Locally advanced prostate cancer--biochemical results from a prospective phase II study of intermittent androgen suppression for men with evidence of prostate-specific antigen recurrence after radiotherapy.
    Bruchovsky N; Klotz L; Crook J; Goldenberg SL
    Cancer; 2007 Mar; 109(5):858-67. PubMed ID: 17265527
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Combination of external irradiation and androgen suppression for prostate cancer: facts and questions].
    Bolla M; Fourneret P; Beneyton V; Tessier A; Jover F; Verry C
    Cancer Radiother; 2010 Oct; 14(6-7):510-4. PubMed ID: 20728391
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Neoadjuvant combined hormonal therapy and radiotherapy with external beam irradiation in prostatic carcinoma].
    Cellini N; Luzi S; Morganti AG; Balducci M; Caiazza A; Salvi G; Trodella L; Valentini V
    Radiol Med; 1997 Apr; 93(4):446-50. PubMed ID: 9244924
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Radiotherapy in cT3 prostatic carcinoma: retrospective comparison between neoadjuvant and adjuvant hormonotherapy.
    Cellini N; Luzi S; Morganti AG; Valentini V; Mantini G; Racioppi M; Smaniotto D; Leone M; Mattiucci GC; Digesù C; Giustacchini M; Destito A; Alcini E
    Urol Int; 2004; 72(1):21-7. PubMed ID: 14730161
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical strategies for improving the radiotherapeutic management of prostate cancer.
    Chuba PJ; Forman JD; Ben-Josef E; Hart KH; Porter AT
    Anticancer Res; 1997; 17(3A):1449-54. PubMed ID: 9179182
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Antiandrogen withdrawal syndrome in the hormonal treatment of metastatic prostatic cancer in hormonal escape].
    Barthélémy Y; Colombel M; Gasman D; Patard JJ; Chopin D; Abbou CC
    Prog Urol; 1996 Feb; 6(1):93-7. PubMed ID: 8624534
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Neoadjuvant androgen deprivation for prostate volume reduction: the optimal duration in prostate cancer radiotherapy.
    Langenhuijsen JF; van Lin EN; Hoffmann AL; Spitters-Post I; Alfred Witjes J; Kaanders JH; Mulders PF
    Urol Oncol; 2011; 29(1):52-7. PubMed ID: 19523856
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.